Effect of MIR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Ding, Jiexia ^a   Li, Meng ^b   Wan, Xingyong ^b   Jin, Xi ^b   Chen, Shaohua ^b   Yu, Chaohui ^b   Li, Youming ^b  

^a HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ASPARTATE AMINOTRANSFERASE; FATTY ACID; MICRORNA; MIRN34 MICRORNA, HUMAN; MIRN34 MICRORNA, MOUSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SIRTUIN 1;

ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CELL LINE; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GENETICS; HUMAN; LIPID DIET; LIVER; MALE; METABOLISM; MOLECULAR GENETICS; NONALCOHOLIC FATTY LIVER; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHOSPHORYLATION;

ADENYLATE KINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BASE SEQUENCE; CELL LINE; DIET, HIGH-FAT; FATTY ACIDS; GENE EXPRESSION PROFILING; HUMANS; LIVER; MALE; MICE, INBRED C57BL; MICRORNAS; MOLECULAR SEQUENCE DATA; NON-ALCOHOLIC FATTY LIVER DISEASE; PHOSPHORYLATION; PPAR ALPHA; SIRTUIN 1; TRANSCRIPTION, GENETIC;

EID: 84940849475     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13729     Document Type: Article

References (38)

1. Dowman, J. K., Armstrong, M. J., Tomlinson, J. W., Newsome, P. N. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 13, 692-702, doi: 10.1111/j.1463-1326.2011.01403.x (2011).
2. Jinek, M., Doudna, J. A. A three-dimensional view of the molecular machinery of RNA interference. Nature 457, 405-412, doi: 10.1038/nature07755 (2009).
3. Krol, J., Loedige, I., Filipowicz, W. The widespread regulation of microRNA biogenesis, function and decay. Nature Reviews Genetics, doi: 10.1038/nrg2843 (2010).
4. Ceccarelli, S., Panera, N., Gnani, D., Nobili, V. Dual Role of MicroRNAs in NAFLD. International Journal of Molecular Sciences 14, 8437-8455, doi: 10.3390/ijms14048437 (2013).
5. Kerr, T. A., Korenblat, K. M., Davidson, N. O. MicroRNAs and liver disease. Translational research: the journal of laboratory and clinical medicine 157, 241-252, doi: 10.1016/j.trsl.2011.01.008 (2011).
6. Lakner, A. M., Bonkovsky, H. L., Schrum, L. W. microRNAs: fad or future of liver disease. World journal of gastroenterology: WJG 17, 2536-2542, doi: 10.3748/wjg.v17.i20.2536 (2011).
7. Lee, J., Kemper, J. K. Controlling SIRT1 expression by microRNAs in health and metabolic disease. Aging 2, 527-534 (2010).
8. Rottiers, V., Naär, A. M. MicroRNAs in metabolism and metabolic disorders. Nature Reviews Molecular Cell Biology 13, 239-250, doi: 10.1038/nrm3313 (2012).
9. Lee, J. et al. A Pathway Involving Farnesoid X Receptor and Small Heterodimer Partner Positively Regulates Hepatic Sirtuin 1 Levels via MicroRNA-34a Inhibition. Journal of Biological Chemistry 285, 12604-12611, doi: 10.1074/jbc.M109.094524 (2010).
10. Cermelli, S., Ruggieri, A., Marrero, J. A., Ioannou, G. N., Beretta, L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE 6, e23937, doi: 10.1371/journal.pone.0023937 (2011).
11. Tryndyak, V. P. et al. Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline-and folate-deficient diet. Toxicol Appl Pharmacol 262, 52-59, doi: 10.1016/j.taap.2012.04.018 (2012).
12. Pogribny, I. P. et al. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Laboratory Investigation 90, 1437-1446, doi: 10.1038/labinvest.2010.113 (2010).
13. Li, S. et al. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res 50, 1756-1765, doi: 10.1194/jlr.M800509-JLR200 (2009).
14. Smith, J. J. et al. Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Systems Biology 3, 31, doi: 10.1186/1752-0509-3-31 (2009).
15. Wahli, W., Braissant, O., Desvergne, B. Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chemistry & biology 2, 261-266 (1995).
16. Dongiovanni, P., Valenti, L. Peroxisome Proliferator-Activated Receptor Genetic Polymorphisms and Nonalcoholic Fatty Liver Disease: Any Role in Disease Susceptibility? PPAR Research 2013, 1-8, doi: 10.1155/2013/452061 (2013).
17. Latruffe, N., Vamecq, J. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism. Biochimie 79, 81-94 (1997).
18. Aoyama, T. et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferatoractivated receptor alpha (PPARalpha). The Journal of biological chemistry 273, 5678-5684 (1998).
19. Nakajima, T. et al. Bezafibrate at Clinically Relevant Doses Decreases Serum/Liver Triglycerides via Down-Regulation of Sterol Regulatory Element-Binding Protein-1c in Mice: A Novel Peroxisome Proliferator-Activated Receptor-Independent Mechanism. Molecular Pharmacology 75, 782-792, doi: 10.1124/mol.108.052928 (2009).
20. Stienstra, R. et al. Peroxisome Proliferator-Activated Receptor ? Protects against Obesity-Induced Hepatic Inflammation. Endocrinology 148, 2753-2763, doi: 10.1210/en.2007-0014 (2007).
21. Reddy, J. K., Hashimoto, T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annual review of nutrition 21, 193-230, doi: 10.1146/annurev.nutr.21.1.193 (2001).
22. Fryer, L. G., Carling, D. AMP-activated protein kinase and the metabolic syndrome. Biochemical Society transactions 33, 362-366, doi: 10.1042/bst0330362 (2005).
23. Hardie, D. G. Minireview: The AMP-Activated Protein Kinase Cascade: The Key Sensor of Cellular Energy Status. Endocrinology 144, 5179-5183, doi: 10.1210/en.2003-0982 (2003).
24. Li, W.-Q. et al. The rno-miR-34 family is upregulated and targets ACSL1 in dimethylnitrosamine-induced hepatic fibrosis in rats. FEBS Journal 278, 1522-1532, doi: 10.1111/j.1742-4658.2011.08075.x (2011).
25. Meng, F. et al. Epigenetic Regulation of miR-34a Expression in Alcoholic Liver Injury. The American Journal of Pathology 181, 804-817, doi: 10.1016/j.ajpath.2012.06.010 (2012).
26. Passi, A. G., Bernardi, C., Soffientini, U., Piacente, F., Tonetti, M. G. Effects of MicroRNAs on Fucosyltransferase 8 (FUT8) Expression in Hepatocarcinoma Cells. PLoS ONE 8, e76540, doi: 10.1371/journal.pone.0076540 (2013).
27. Chiu, L. Y. et al. Identification of differentially expressed microRNAs in human hepatocellular adenoma associated with type I glycogen storage disease: a potential utility as biomarkers. Journal of gastroenterology 49, 1274-1284, doi: 10.1007/s00535-013-0890-2 (2014).
28. Dang, Y., Luo, D., Rong, M., Chen, G. Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PloS one 8, e61054, doi: 10.1371/journal.pone.0061054 (2013).
29. Cheung, O. et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 48, 1810-1820, doi: 10.1002/hep.22569 (2008).
30. Yamada, H. et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clinica Chimica Acta 424, 99-103, doi: 10.1016/j.cca.2013.05.021 (2013).
31. Castro, R. E. et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol 58, 119-125, doi: 10.1016/j.jhep.2012.08.008 (2013).
32. Guarente, L. Sirtuins as potential targets for metabolic syndrome. Nature 444, 868-874, doi: 10.1038/nature05486 (2006).
33. Gerhart-Hines, Z. et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J 26, 1913-1923, doi: 10.1038/sj.emboj.7601633 (2007).
34. Choi, S.-E. et al. Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. Aging Cell 12, 1062-1072, doi: 10.1111/acel.12135 (2013).
35. Bonnefont, J. P. et al. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Molecular aspects of medicine 25, 495-520, doi: 10.1016/j.mam.2004.06.004 (2004).
36. Lenz, L. S. et al. Adipocyte-specific Inactivation of Acyl-CoA Synthetase Fatty Acid Transport Protein 4 (Fatp4) in Mice Causes Adipose Hypertrophy and Alterations in Metabolism of Complex Lipids under High Fat Diet. Journal of Biological Chemistry 286, 35578-35587, doi: 10.1074/jbc.M111.226530 (2011).
37. Kahn, B. B., Alquier, T., Carling, D., Hardie, D. G. AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabolism 1, 15-25, doi: 10.1016/j.cmet.2004.12.003 (2005).
38. Hou, X. et al. SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein Kinase. Journal of Biological Chemistry 283, 20015-20026, doi: 10.1074/jbc.M802187200 (2008).